Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.60 |
| ▸ | GSK3A | P49840 | 4/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140975 | 0.86 | MGLL (0.72) | MGLLGSK3AGSK3BFAAHPTGS1 | |
| SCHEMBL17114059 | 0.79 | KMT2A (0.42) | FAAHIDO1HTR2CCMA1 | |
| SCHEMBL12204465 | 0.79 | KMT2A (0.60) | — | |
| SCHEMBL6388547 | 0.78 | MGLL (0.60) | MGLLGSK3AGSK3BFAAHPTGS1 | |
| SCHEMBL28411433 | 0.78 | MGLL (0.60) | MGLLGSK3AGSK3BFAAHIDO1 | |
| SCHEMBL20804240 | 0.78 | MGLL (0.60) | MGLLGSK3AGSK3BFAAHPTGS1 | |
| SCHEMBL7224603 | 0.78 | MGLL (0.60) | MGLLGSK3AGSK3BFAAHPTGS1 | |
| SCHEMBL7224723 | 0.78 | MGLL (0.60) | MGLLGSK3AGSK3BFAAHPTGS1 | |
| SCHEMBL30799219 | 0.77 | MEN1 (0.51) | FAAHIDO1HTR2C | |
| SCHEMBL27385975 | 0.77 | MEN1 (0.51) | FAAHIDO1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089962-B1 | RADIOIODINATED COMPOUNDS | NUTECH VENTURES (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3089962-B1 | RADIOIODINATED COMPOUNDS | NUTECH VENTURES (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10053423-B2 | Radioiodinated compounds | NUTECH VENTURES (US) | 2018-08-21 | — | — | US | disclosed |
| CN-106536490-A | Radioiodinated compounds | 纽泰克温图斯公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20160326109-A1 | RADIOIODINATED COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2016-11-10 | — | — | US | disclosed |
| US-20160326109-A1 | RADIOIODINATED COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2016-11-10 | — | — | US | disclosed |
| US-20160326109-A1 | RADIOIODINATED COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2016-11-10 | — | — | US | disclosed |
| EP-3089962-A2 | RADIOIODINATED COMPOUNDS | Nutech Ventures (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015147950-A2 | RADIOIODINATED COMPOUNDS | NUTECH VENTURES (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015147950-A2 | RADIOIODINATED COMPOUNDS | NUTECH VENTURES (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2912011-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals Inc. (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014066772-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2014066772-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | Ground Fluor Pharmaceuticals, Inc. (US) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326109-A1 | RADIOIODINATED COMPOUNDS | SLC7A5, DDC, PAICS | MGLL 3377/4885GSK3A 3973/4885GSK3B 3819/4885 |
| US-20140121371-A1 | PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS | ABL1, ARSA, AADAC | MGLL 969/4885GSK3A 4116/4885GSK3B 3994/4885 |
| US-10053423-B2 | Radioiodinated compounds | SLC7A5, DDC, PAICS | MGLL 3377/4885GSK3A 3973/4885GSK3B 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.